Summary
| Excerpt |
|---|
Phase II Study of 3'-Deoxy-3'-18F Fluorothymidine (FLT) in Invasive Breast Cancer Main Objective: To ACRIN 6688, a [18F]-fluorothymidine (FLT) imaging study using positron emission tomography (PET), was designed to evaluate the relationship between [18F] FLT uptake parameters and pathologic complete response to neoadjuvant therapy of the primary tumor in patients with locally advanced breast cancer.Design Summary: Patients with locally advanced breast cancer who are candidates
Participant Eligibility and Enrollment: Criteria for inclusion were patients with pathologically confirmed breast cancer and determined to be a candidate for primary systemic (neoadjuvant) therapy and for whom subsequent definitiate surgery is planned (according to current clinical guidelines) may be eligible for this trial. Participants will be required to have three 2-day imaging sessions using FLT and FDG-PET/CT to evaluate therapy response (baseline, mid-treatment, and just prior to surgical resection of residual tumor)surgical resection of residual primary tumor following completion of neoadjuvant therapy is planned. The study was open to enrollment from September 2009 to September 2012. Final accrual to the study was 90 patients, of which 80 were included in the analysis. |
Much more information about this data set can be found https://www.acrin.org/6688_protocol.aspx and for ACRIN in general here. https://www.acrin.org/
...